AI assistant
WEST PHARMACEUTICAL SERVICES INC — Director's Dealing 2016
Jun 2, 2016
30339_dirs_2016-06-02_be0a874a-6d9c-418c-8ca7-9a8a8ee9d7db.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: WEST PHARMACEUTICAL SERVICES INC (WST)
CIK: 0000105770
Period of Report: 2016-06-02
Reporting Person: Malone Daniel (Vice President & Controller)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-06-02 | Common Stock | M | 3950.0000 | $22.4850 | Acquired | 30665.5015 | Direct |
| 2016-06-02 | Common Stock | S | 3950.0000 | $74.9511 | Disposed | 26715.5015 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-06-02 | Stock Option (Right to Buy) | $22.4850 | M | 3950.0000 | Disposed | 2017-02-27 | Common Stock (3950.0000) | Direct |
Footnotes
F1: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $74.76 to $75.08, inclusive. The reporting person undertakes to provide to West PharmaceuticalServices, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate pricewithin the range in this footnote.
F2: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.